# Niox Group (NIOX.L) fundamentals

Data as of 2026-09-08. LSE, United Kingdom. Sector: Healthcare / Biotechnology. Price 67p, market value 282 millionp.

## Valuation
- **P/E (trailing): 33.5×** (5-yr avg 4068.0×, 3-yr avg 4816.1×). Niox Group trades at 33.5× trailing earnings, well below its own five-year average of 4068.0×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 17.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.18**. A PEG of 0.18 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.1×**. Each dollar of revenue is priced at 3.1×.
- **Price / book: 4.1×**. The shares trade at 4.1× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 9.7×**. Enterprise value is 9.7× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 11.8%** (5-yr avg 0.0%). Free cash flow equals 11.8% of the market value, above its five-year average of 0.0%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 3.0%**. The inverse of the P/E: 3.0% of the price is earned each year.

## Profitability
- **Gross margin: 63.8%**. Niox Group keeps 63.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 20.3%**. 20.3% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 14.4%**. 14.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 9.5%**. 9.5% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 18.4%**. Return on all capital, debt included, is 18.4%: comfortably above what that capital costs.
- **Return on assets: 14.0%**. Each dollar of assets produces 14.0% of profit.

## Growth
- **Revenue growth (1 yr): 16.5%** (3-yr 15.9%/yr, 5-yr 15.3%/yr). Revenue grew 16.5% over the last year, against 15.3% a year compounded over five years.
- **EPS growth (1 yr): 97.6%** (3-yr -23.3%/yr). Earnings per share rose 97.6%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 33.2%/yr**. Free cash flow has compounded at 33.2% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Niox Group holds more cash than debt.
- **Interest coverage: 46.0×**. Operating profit covers interest 46.0× over, a safe margin.
- **Current ratio: 3.81** (quick 3.20). Current assets cover the next year's liabilities 3.81 times.
- **Altman Z-score: 22.78**. A Z-score of 22.78 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 8/9**. 8 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 2.29%** (0p per share, trailing). Niox Group yields 2.29%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 71%** (28% of free cash flow). 71% of earnings goes out as dividends, leaving a thin cushion.
- **Consecutive years of increases: 1**. 1 straight year of increases.
- **Shareholder yield: 9.8%**. Dividends plus net buybacks return 9.8% of the market value a year.

## Price and momentum
- **Total return (1 yr): -8.6%** (YTD 1.8%, 3-mo 12.7%). The shares are down 8.6% over twelve months including dividends.
- **From 52-week high: -11.8%** (24.4% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 0.04** (volatility 31%). Beta of 0.04 against the FTSE All-Share: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NIOX.L · Page: https://foliofundamentals.com/stocks/niox.l

Not investment advice.